Introduction: A Growth Hormone Fragment With a Unique Story
AOD-9604 occupies a singular position in peptide science. It is a modified 16-amino-acid fragment derived from the C-terminal region (residues 176-191) of human growth hormone (hGH), engineered to isolate the lipolytic (fat-metabolizing) properties of hGH from its growth-promoting, IGF-1-stimulating, and diabetogenic effects. Unlike most research peptides that exist only in preclinical literature, AOD-9604 has been tested in six randomized, placebo-controlled human clinical trials involving over 900 participants — an extraordinarily robust safety dataset for a research-stage compound. It holds FDA GRAS (Generally Recognized As Safe) status as a food ingredient. And yet, it was never approved as a pharmaceutical drug, after its largest efficacy trial produced statistically significant but commercially insufficient weight loss results.[1][2]
For researchers working with metabolic peptides, AOD-9604 provides a valuable tool for studying adipocyte-specific lipolytic pathways independent of the broader hormonal effects of growth hormone. This guide covers the complete scientific profile — from molecular mechanism through clinical trial history to practical laboratory handling. For a broader overview of the research peptide landscape, see our article on what research peptides are.
Discovery and Development
The scientific foundation for AOD-9604 emerged from a fundamental observation in endocrinology: human growth hormone possesses both somatogenic (growth-promoting) and lipolytic (fat-metabolizing) activities, and these functions map to different structural domains of the molecule. In the early 1990s, Professor Frank Ng and colleagues at Monash University in Melbourne, Australia, identified that the C-terminal region of hGH — specifically amino acids 176 through 191 — was responsible for much of the hormone's lipolytic activity. This 16-amino-acid sequence could stimulate fat breakdown in laboratory models without triggering IGF-1 release or promoting cellular proliferation.[1][3]
The native hGH fragment 176-191 was further modified by substituting a tyrosine residue for the phenylalanine at the N-terminal position, creating the compound designated AOD-9604 (Anti-Obesity Drug 9604 — the 9,604th compound in its research series). This seemingly minor modification improved the peptide's stability and enhanced its lipolytic potency in preclinical testing. Metabolic Pharmaceuticals, an Australian biotechnology company, advanced AOD-9604 through preclinical development and into human clinical trials during the early 2000s. For more on the specific structural differences between AOD-9604 and the unmodified fragment, see our article on AOD-9604 vs hGH Fragment 176-191.[1][2]
Molecular Structure
AOD-9604 is a synthetic peptide consisting of 17 amino acids (the 16 C-terminal residues of hGH plus the added N-terminal tyrosine). Its sequence corresponds to hGH residues 176-191 with the Tyr substitution. The peptide contains a disulfide bond between Cys183 and Cys189, which is important for structural integrity and biological activity. The molecular weight is approximately 1,817 Da — placing it firmly in the small peptide category, substantially smaller than full-length hGH (22 kDa, 191 amino acids). This size difference is central to its pharmacological selectivity: AOD-9604 is too small to engage the GH receptor's binding interface, which requires interaction with multiple discontinuous regions of the full-length hGH molecule.[1][2]
Mechanism of Action
AOD-9604 exerts its metabolic effects through a mechanism that is distinct from — and independent of — the classical GH receptor signaling pathway. The peptide does not bind to the GH receptor, does not stimulate IGF-1 production, does not activate the JAK2-STAT5 signaling cascade that mediates GH's growth-promoting effects, and does not produce the insulin resistance and hyperglycemia associated with supraphysiological GH levels. For a detailed mechanistic analysis, see our article on AOD-9604 mechanism of action.[1][3]
Beta-3 Adrenergic Receptor Upregulation
The primary identified mechanism involves upregulation of beta-3 adrenergic receptor (β3-AR) expression in adipose tissue. A landmark study by Heffernan et al. (2001) in Endocrinology demonstrated that chronic treatment with both hGH and AOD-9604 in obese mice produced significant body weight and body fat reduction that correlated with increased β3-AR RNA expression. In obese mice, β3-AR expression is characteristically suppressed; both hGH and AOD-9604 restored these repressed levels to those comparable with lean animals. Critically, the importance of β3-AR was verified using knockout mice: when β3-AR was genetically deleted, both hGH and AOD-9604 completely failed to produce the weight loss and lipolytic effects observed in wild-type controls. This genetic evidence establishes β3-AR as an essential mediator of AOD-9604's lipolytic activity.[3]
Lipolysis Stimulation and Lipogenesis Inhibition
AOD-9604 stimulates lipolysis (the breakdown of stored triglycerides into glycerol and free fatty acids) while simultaneously inhibiting lipogenesis (the de novo formation of fat). This dual action — promoting fat breakdown while preventing fat formation — is the pharmacological basis for its anti-obesity rationale. The lipolytic effect involves increased intracellular cAMP in adipocytes through β3-AR-mediated Gs-coupled signaling, which activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) to mobilize stored triglycerides. Preclinical studies showed that AOD-9604 preferentially released fat from obese adipocytes while having minimal effect on lean fat cells — a selectivity that may reflect the differential β3-AR expression levels in obese versus lean adipose tissue.[1][3]
No IGF-1 Stimulation, No Diabetogenic Effects
The defining pharmacological advantage of AOD-9604 over full-length hGH is the absence of growth-promoting and metabolically adverse effects. In all preclinical and clinical studies, AOD-9604 did not stimulate IGF-1 production, did not affect glucose metabolism, did not impair insulin sensitivity, and did not cause insulin resistance. Ligand binding experiments confirmed that AOD-9604 is not a high-affinity ligand for the GH receptor. This clean separation of lipolytic activity from the broader endocrine effects of GH is what made AOD-9604 attractive as both a research tool and a potential therapeutic — it allows researchers to study adipocyte-specific lipolytic pathways without confounding anabolic or endocrine influences.[1][2]
Clinical Trial History
AOD-9604 is one of the few research peptides with a substantial human clinical trial database. Metabolic Pharmaceuticals conducted six randomized, double-blind, placebo-controlled trials between 2001 and 2007, testing both intravenous and oral formulations at various doses.[2][4]
The early-phase trials (METAOD001 through METAOD004) established safety and tolerability. METAOD001 tested single intravenous doses (25-400 μg/kg) in 15 healthy males and found the compound safe and well-tolerated. METAOD002 confirmed no effect on IGF-1 levels in obese subjects. METAOD003 and METAOD004 demonstrated oral bioavailability and safety at doses up to 54 mg/day. The Phase IIb trial (METAOD005, approximately 300 obese adults, 12 weeks oral dosing at 1-30 mg/day) showed statistically significant weight loss — subjects receiving AOD-9604 at 1 mg/day lost an average of 2.6 kg compared to 0.8 kg with placebo in a 12-week period.[2][4]
The pivotal Phase IIb OPTIONS trial (METAOD006, 536 subjects, 24 weeks, oral doses of 0.25, 0.5, and 1 mg/day) ultimately determined the compound's pharmaceutical fate. While AOD-9604 was confirmed safe and well-tolerated — with no serious adverse events and no hormonal disruption — the weight loss at 24 weeks was modest and did not reach the threshold of commercial viability. Metabolic Pharmaceuticals discontinued development in 2007. The failure was one of efficacy magnitude, not safety: the 1.8 kg difference from placebo, while statistically significant, was considered insufficient for a pharmaceutical obesity indication in an era when the industry expected larger effect sizes.[4][5]
FDA GRAS Status
Following the clinical trial program, AOD-9604 received FDA GRAS (Generally Recognized As Safe) status as a food ingredient, conditional on publication of pre-existing safety data. This designation — based on the cumulative safety evidence from six human clinical trials, extensive toxicology studies in rats and cynomolgus monkeys (NOAEL of 100 mg/kg/day in rats and 50 mg/kg/day in monkeys under chronic conditions), and the absence of immunogenicity — permits its use in foods, beverages, and dietary supplements at doses up to 1 mg/day. GRAS status is a food safety classification, not a drug approval — it does not authorize AOD-9604 for therapeutic or pharmaceutical use. For a detailed analysis of the regulatory history, see our article on AOD-9604 FDA GRAS history.[2]
Emerging Research: Cartilage Repair and Chondroprotection
A newer and increasingly active research area involves AOD-9604's potential effects on cartilage and joint health — an application entirely separate from its original anti-obesity rationale. Preclinical studies have demonstrated chondroprotective and potentially chondroregenerative properties. In a rabbit osteoarthritis model, intra-articular injection of AOD-9604 combined with hyaluronic acid enhanced cartilage regeneration compared to either treatment alone, with the combination group showing substantially faster lameness recovery (11±4 days vs 25±2 days for controls). In vitro studies have shown that AOD-9604 stimulates proteoglycan synthesis in chondrocyte cultures, suggesting direct anabolic effects on cartilage tissue.[6]
The mechanism underlying these chondroprotective effects is not fully characterized and appears to be independent of the β3-AR pathway that mediates the lipolytic activity. This raises the possibility that AOD-9604 possesses multi-functional properties mediated through different signaling pathways in different tissue contexts — a phenomenon not uncommon with bioactive peptide fragments. Research in this area remains preclinical, and human evidence for cartilage repair applications is currently absent.
Safety Profile
The safety database for AOD-9604 is unusually robust for a research peptide. Across six human clinical trials with over 900 participants, no serious adverse events were attributed to the compound. Specific safety findings include no effect on IGF-1 levels at any dose tested, no changes in glucose metabolism or insulin sensitivity (up to 24 weeks of daily dosing), no immunogenicity (absence of anti-AOD-9604 antibodies in all animal and human studies), no evidence of systemic hormonal disruption, and a side effect profile comparable to placebo in controlled trials.[2][4]
AOD-9604 is prohibited by the World Anti-Doping Agency (WADA) under the category of peptide hormones, growth factors, and mimetics. Athletes subject to drug testing must not use this compound. Detection methods with limits of approximately 50 pg/mL have been validated, and metabolite profiling has identified six potential metabolites, with the metabolite CRSVEGSCG showing greater serum stability than the parent compound.[5]
Handling, Reconstitution, and Storage
AOD-9604 is supplied as a lyophilized (freeze-dried) powder and follows standard peptide handling protocols. For detailed guidance on peptide reconstitution techniques, see our peptide reconstitution guide. For understanding the principles behind lyophilized peptide stability, see our article on lyophilized peptides.
Lyophilized AOD-9604 should be stored at -20°C for long-term preservation. The powder should appear white to off-white; yellow discoloration, excessive clumping, or a collapsed appearance may indicate degradation. Reconstitution should be performed using bacteriostatic water, added slowly along the vial wall with gentle swirling — never vigorous shaking, which can damage the peptide through mechanical stress. The reconstituted solution should be crystal clear without particles or cloudiness; any turbidity suggests aggregation or contamination. Reconstituted AOD-9604 should be stored at 2-8°C and used within approximately 28 days. For comprehensive guidance on stability factors, see our AOD-9604 stability and storage guide.[1]
Quality Verification
Researchers should verify AOD-9604 purity and identity through Certificates of Analysis (CoA) showing HPLC purity ≥98% and confirmed amino acid sequence. Third-party testing is essential for research-grade compounds to ensure that the peptide matches its stated identity and purity. For guidance on interpreting CoAs and understanding analytical methods, see our articles on certificates of analysis, HPLC testing, and third-party testing.
Context Within the Metabolic Research Landscape
AOD-9604 targets a specific metabolic pathway — adipocyte lipolysis through β3-AR upregulation — that is mechanistically distinct from the incretin-based approaches now dominating the obesity therapeutics landscape. While GLP-1 receptor agonists like GLP-1 agonist peptide and GLP dual agonist peptide reduce appetite through central nervous system effects and delay gastric emptying, AOD-9604's mechanism is peripheral, acting directly on fat cells without affecting appetite or food intake. Exercise mimetics such as SLU-PP-915 increase energy expenditure through ERR nuclear receptor activation — yet another orthogonal pathway. Multi-receptor agonists like NA-931 (Bioglutide) combine incretin and growth factor signaling. For more on AOD-9604's specific metabolic effects, see our existing article on AOD-9604 fat loss and metabolic health.
Understanding how these different strategies compare and potentially complement each other is essential for researchers navigating the metabolic therapeutics landscape. AOD-9604's value as a research tool lies precisely in its mechanistic selectivity — it allows the study of β3-AR-mediated lipolysis in isolation from the hormonal, appetitive, and gastrointestinal effects that accompany other metabolic interventions.
Summary
AOD-9604 is a modified C-terminal fragment of human growth hormone that selectively stimulates lipolysis and inhibits lipogenesis through β3-adrenergic receptor upregulation, without affecting IGF-1, glucose metabolism, or insulin sensitivity. Its clinical trial history (six human trials, 900+ participants) provides an unusually robust safety profile for a research peptide, and its FDA GRAS status as a food ingredient reflects this safety evidence. While its pharmaceutical development for obesity was discontinued in 2007 due to modest efficacy, the compound remains valuable for metabolic research and is the subject of emerging investigation in cartilage repair. For researchers, AOD-9604 offers a well-characterized tool for studying adipocyte-specific metabolic pathways independent of the broader endocrine effects of growth hormone.
